Salarius Pharmaceuticals Stock Buy Hold or Sell Recommendation
| SLRX Stock | USD 1.12 0.11 8.94% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Salarius Pharmaceuticals is 'Cautious Hold'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Salarius Pharmaceuticals given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Salarius Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Salarius Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Salarius Stock please use our How to Invest in Salarius Pharmaceuticals guide. In addition, we conduct extensive research on individual companies such as Salarius and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Salarius Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Salarius |
Execute Salarius Pharmaceuticals Buy or Sell Advice
The Salarius recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Salarius Pharmaceuticals. Macroaxis does not own or have any residual interests in Salarius Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Salarius Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Insignificant | Details | |
Volatility | Out of control | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Very Weak | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Salarius Pharmaceuticals Trading Alerts and Improvement Suggestions
| Salarius Pharmaceuticals is way too risky over 90 days horizon | |
| Salarius Pharmaceuticals may become a speculative penny stock | |
| Salarius Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Salarius Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (12.54 M) with loss before overhead, payroll, taxes, and interest of (15.84 M). | |
| Salarius Pharmaceuticals currently holds about 22.65 M in cash with (12.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Salarius Pharmaceuticals has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase ... |
Salarius Pharmaceuticals Returns Distribution Density
The distribution of Salarius Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Salarius Pharmaceuticals' future price movements. The chart of the probability distribution of Salarius Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Salarius Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Salarius Pharmaceuticals returns is essential to provide solid investment advice for Salarius Pharmaceuticals.
| Mean Return | 0.87 | Value At Risk | -8.86 | Potential Upside | 11.41 | Standard Deviation | 18.01 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Salarius Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Salarius Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Salarius Pharmaceuticals, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Salarius Pharmaceuticals back and forth among themselves.
| Shares | Ubs Group Ag | 2024-12-31 | 7.1 K | Advisor Group Holdings, Inc. | 2024-12-31 | 162 | Bank Of America Corp | 2024-12-31 | 11.0 | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 7.0 | Blackrock Inc | 2024-12-31 | 1.0 | Sbi Securities Co Ltd | 2024-12-31 | 1.0 | Wells Fargo & Co | 2024-09-30 | 0.0 | Tower Research Capital Llc | 2024-12-31 | 0.0 | Northern Trust Investments N A | 2024-12-31 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 0.0 | Citigroup Inc | 2024-12-31 | 0.0 |
Salarius Pharmaceuticals Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 7.4M | 18.1M | (17.1M) | (6.2M) | (5.6M) | (5.3M) | |
| Free Cash Flow | (10.3M) | (10.2M) | (19.1M) | (12.8M) | (14.8M) | (15.5M) | |
| Depreciation | 18.1K | 19.2K | 6.7K | 10.1K | 9.0K | 8.6K | |
| Other Non Cash Items | (258.6K) | (44.7K) | 10.8M | 130K | 149.5K | 142.0K | |
| Net Income | (7.4M) | (12.8M) | (31.6M) | (12.5M) | (14.4M) | (15.1M) | |
| End Period Cash Flow | 11.1M | 29.2M | 12.1M | 5.9M | 5.3M | 5.0M | |
| Change To Netincome | (559.7K) | 60.8K | 514.4K | 11.6M | 13.4M | 14.1M | |
| Change To Inventory | 1.2K | 3.9M | (2.2M) | (1.0) | (1.15) | (1.09) |
Salarius Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Salarius Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Salarius Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Salarius stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.87 | |
β | Beta against Dow Jones | 3.99 | |
σ | Overall volatility | 19.03 | |
Ir | Information ratio | 0.05 |
Salarius Pharmaceuticals Volatility Alert
Salarius Pharmaceuticals is displaying above-average volatility over the selected time horizon. Salarius Pharmaceuticals is a potential penny stock. Although Salarius Pharmaceuticals may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Salarius Pharmaceuticals. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Salarius instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Salarius Pharmaceuticals Fundamentals Vs Peers
Comparing Salarius Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Salarius Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Salarius Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Salarius Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Salarius Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Salarius Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Salarius Pharmaceuticals to competition |
| Fundamentals | Salarius Pharmaceuticals | Peer Average |
| Return On Equity | -1.11 | -0.31 |
| Return On Asset | -0.53 | -0.14 |
| Current Valuation | (1.01 M) | 16.62 B |
| Shares Outstanding | 1.58 M | 571.82 M |
| Shares Owned By Insiders | 2.29 % | 10.09 % |
| Shares Owned By Institutions | 5.23 % | 39.21 % |
| Number Of Shares Shorted | 19.34 K | 4.71 M |
| Price To Book | 0.67 X | 9.51 X |
| Price To Sales | 18.12 X | 11.42 X |
| Gross Profit | (15.84 M) | 27.38 B |
| EBITDA | (12.88 K) | 3.9 B |
| Net Income | (12.54 M) | 570.98 M |
| Cash And Equivalents | 22.65 M | 2.7 B |
| Cash Per Share | 10.09 X | 5.01 X |
| Total Debt | 289.64 K | 5.32 B |
| Debt To Equity | 0 % | 48.70 % |
| Current Ratio | 8.31 X | 2.16 X |
| Book Value Per Share | 2.03 X | 1.93 K |
| Cash Flow From Operations | (12.85 M) | 971.22 M |
| Earnings Per Share | (5.14) X | 3.12 X |
| Target Price | 26.0 | |
| Number Of Employees | 2 | 18.84 K |
| Beta | 0.84 | -0.15 |
| Market Capitalization | 1.95 M | 19.03 B |
| Total Asset | 6.59 M | 29.47 B |
| Retained Earnings | (76.35 M) | 9.33 B |
| Working Capital | 5.22 M | 1.48 B |
| Current Liabilities | 1.97 M | 7.9 B |
| Net Asset | 6.59 M |
Note: Acquisition by Rosenblum Mark J of 6432 shares of Salarius Pharmaceuticals subject to Rule 16b-3 [view details]
Salarius Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Salarius . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 12574.06 | |||
| Daily Balance Of Power | (0.65) | |||
| Rate Of Daily Change | 0.91 | |||
| Day Median Price | 1.15 | |||
| Day Typical Price | 1.14 | |||
| Price Action Indicator | (0.08) | |||
| Period Momentum Indicator | (0.11) | |||
| Relative Strength Index | 43.24 |
About Salarius Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Salarius Pharmaceuticals? Buying financial instruments such as Salarius Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Salarius Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Real Estate Thematic Idea Now
Real Estate
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Real Estate theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Real Estate Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Salarius Stock Analysis
When running Salarius Pharmaceuticals' price analysis, check to measure Salarius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Salarius Pharmaceuticals is operating at the current time. Most of Salarius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Salarius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Salarius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Salarius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.